Cancer immunoprevention: Tracking down persistent tumor antigens

Trends in Immunology

Volumn 24, Issue 2, 2003, Pages 62-66

  Lollini, Pier Luigi ^a   Forni, Guido ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; TUMOR VACCINE;

CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICINE; NONHUMAN; PATHOGENICITY; REVIEW; RISK FACTOR; T LYMPHOCYTE; TUMOR GROWTH;

EID: 0037303197     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)00030-3     Document Type: Article

References (59)

1. Old L.J., Chen Y.T. New paths in human cancer serology. J. Exp. Med. 187:1998;1163-1167.
2. Klein G., et al. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20:1960;1561-1568.
3. Hewitt H.B., et al. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer. 33:1976;241-259.
4. r . T. I. - terminal patient or still curable? Immunol. Today. 1:1980;5-6.
5. Uyttenhove C., et al. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp. Med. 152:1980;1175-1183.
6. Boon T. Antigenic tumor cell variants obtained with mutagens. Adv. Cancer Res. 39:1983;121-151.
7. Boon T., et al. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365.
8. Wang R.F., Rosenberg S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170:1999;85-100.
9. Tureci O., et al. Serological analysis of human tumor antigens: molecular definition and implications. Mol. Med. Today. 3:1997;342-349.
10. Scanlan M.J., et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immunity. 1:2001;4.
11. Bocchia M., et al. Antitumor vaccination: where we stand. Haematologica. 85:2000;1172-1206.
12. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol. Immunother. 48:1999;382-385.
13. + T-cell adoptive immunotherapy. Immunity. 13:2000;265-276.
14. Singh S., et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:1992;139-146.
15. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:2002;549-555.
16. Cahill D.P., et al. Genetic instability and Darwinian selection in tumours. Trends Cell Biol. 9:1999;M57-M60.
17. Riker A., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery. 126:1999;112-120.
18. Parmiani G., et al. T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immunity. 2:2002;6.
19. Palmowski M.J., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168:2002;4391-4398.
20. Schultze J.L., Vonderheide R.H. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol. 22:2001;516-523.
21. Jonsen A.R., et al. The advent of the 'unpatients'. Nat. Med. 2:1996;622-624.
22. Coulie P.G. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol. Med. Today. 3:1997;261-268.
23. Forni G., et al. Immunoprevention of cancer: is the time ripe? Cancer Res. 60:2000;2571-2575.
24. Finn O.J., Forni G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14:2002;172-177.
25. Gendler S.J., Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol. Med. 7:2001;471-475.
26. Jonkers J., Berns A. Conditional mouse models of sporadic cancer. Nat. Rev. Cancer. 2:2002;251-265.
27. Di Carlo E., et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 79:1999;1261-1269.
28. Cefai D., et al. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int. J. Cancer. 83:1999;393-400.
29. Nanni P., et al. Combined allogeneic tumor-cell vaccination and systemic interleukin-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194:2001;1195-1205.
30. Esserman L.J., et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47:1999;337-342.
31. Dakappagari N.K., et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60:2000;3782-3789.
32. Amici A., et al. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother. 47:1998;183-190.
33. Rovero S., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165:2000;5133-5142.
34. Rovero S., et al. Insertion of the DNA for the 163-171 peptide of IL1-β enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther. 8:2001;447-452.
35. Pupa S.M., et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther. 8:2001;75-79.
36. Amici A., et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 7:2000;703-706.
37. Varesio L., et al. Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor. Cancer Res. 39:1979;4983-4988.
38. Forni G., et al. Immune recognition of tumor cells in vivo. I. Role of H-2 gene products in T-lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells. Eur. J. Immunol. 12:1982;664-670.
39. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science. 272:1996;54-60.
40. Ada G. Vaccines and vaccination. New Engl. J. Med. 345:2001;1042-1053.
41. Old L.J., et al. Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J. Exp. Med. 127:1968;523-539.
42. Garrido F., Algarra I. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 83:2001;117-158.
43. Nanni P., et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer. 87:2000;186-194.
44. Uhr J.W., et al. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med. 3:1997;505-509.
45. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin. Cancer Biol. 11:2001;297-306.
46. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature. 411:2001;380-384.
47. Torchilin V.P., et al. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 22:2001;424-427.
48. Gendler S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia. 6:2001;339-353.
49. Timmerman J.M. Vaccine therapies for non-Hodgkin's lymphoma. Curr. Treat. Options Oncol. 3:2002;307-315.
50. Pedersen I.M., et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 99:2002;1314-1319.
51. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365.
52. Brivanlou A.H., Darnell J.E. Jr. Signal transduction and the control of gene expression. Science. 295:2002;813-818.
53. Chen Y.-T., et al. Identification of human tumor antigens by serological expression cloning. Rosenberg S.A. Principles and Practice of the Biologic Therapy of Cancer. 2000;557-570 Lippincott Williams & Wilkins.
54. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
55. Hemler M.E. Specific tetraspanin functions. J. Cell Biol. 155:2001;1103-1107.
56. Haass C. New hope for Alzheimer disease vaccine. Nat. Med. 8:2002;1195-1196.
57. Smith I.E. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs. 12:2001;S3-10.
58. Dudley M.E., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.
59. Abken H., et al. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol. 23:2002;240-245.